ID   K562/MTX-4
AC   CVCL_F1X8
RX   PubMed=2465288;
CC   Population: Caucasian.
CC   Doubling time: 59.5 +- 1.3 hours (PubMed=2465288).
CC   Selected for resistance to: ChEBI; CHEBI_44185; Methotrexate (MTX).
CC   Sequence variation: Gene fusion; HGNC; HGNC:76; ABL1 + HGNC; HGNC:1014; BCR; Name(s)=BCR-ABL1, BCR-ABL; Note=BCR exon 14 fused to ABL1 exon 2 (b3a2 transcript) (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C9110; Blast phase chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0004 ! K-562
SX   Female
AG   53Y
CA   Cancer cell line
DT   Created: 27-11-25; Last updated: 27-11-25; Version: 1
//
RX   PubMed=2465288; DOI=10.1111/j.1349-7006.1988.tb01549.x; PMCID=PMC5917644;
RA   Koizumi, Shoichi
RT   "Impairment of methotrexate (MTX)-polyglutamate formation of
RT   MTX-resistant K562 cell lines.";
RL   Jpn. J. Cancer Res. 79:1230-1237(1988).
//